Connection

NANCY WEIGEL to Humans

This is a "connection" page, showing publications NANCY WEIGEL has written about Humans.
Connection Strength

0.543
  1. Cistrome and transcriptome analysis identifies unique androgen receptor (AR) and AR-V7 splice variant chromatin binding and transcriptional activities. Sci Rep. 2022 03 30; 12(1):5351.
    View in: PubMed
    Score: 0.020
  2. Isoform-specific Activities of Androgen Receptor and its Splice Variants in Prostate Cancer Cells. Endocrinology. 2021 03 01; 162(3).
    View in: PubMed
    Score: 0.018
  3. Androgen receptor and its splice variant, AR-V7, differentially induce mRNA splicing in prostate cancer cells. Sci Rep. 2021 01 14; 11(1):1393.
    View in: PubMed
    Score: 0.018
  4. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Oncotarget. 2017 Jul 04; 8(27):44447-44464.
    View in: PubMed
    Score: 0.014
  5. Differential regulation of metabolic pathways by androgen receptor (AR) and its constitutively active splice variant, AR-V7, in prostate cancer cells. Oncotarget. 2015 Oct 13; 6(31):31997-2012.
    View in: PubMed
    Score: 0.013
  6. Hormones and Cancer--Looking Forward. Horm Cancer. 2015 Dec; 6(5-6):189-90.
    View in: PubMed
    Score: 0.013
  7. Cyclin A2 and its associated kinase activity are required for optimal induction of progesterone receptor target genes in breast cancer cells. J Steroid Biochem Mol Biol. 2014 Oct; 144 Pt B:471-82.
    View in: PubMed
    Score: 0.012
  8. Androgen receptor and its splice variant, AR-V7, differentially regulate FOXA1 sensitive genes in LNCaP prostate cancer cells. Int J Biochem Cell Biol. 2014 Sep; 54:49-59.
    View in: PubMed
    Score: 0.012
  9. The prostate cancer TMPRSS2:ERG fusion synergizes with the vitamin D receptor (VDR) to induce CYP24A1 expression-limiting VDR signaling. Endocrinology. 2014 Sep; 155(9):3262-73.
    View in: PubMed
    Score: 0.012
  10. Androgen receptors in hormone-dependent and castration-resistant prostate cancer. Pharmacol Ther. 2013 Dec; 140(3):223-38.
    View in: PubMed
    Score: 0.011
  11. Phosphorylation: a fundamental regulator of steroid receptor action. Trends Endocrinol Metab. 2013 Oct; 24(10):515-24.
    View in: PubMed
    Score: 0.011
  12. Androgen receptor splice variants are resistant to inhibitors of Hsp90 and FKBP52, which alter androgen receptor activity and expression. Steroids. 2013 Jun; 78(6):548-54.
    View in: PubMed
    Score: 0.011
  13. Targeted disruption of the p160 coactivator interface of androgen receptor (AR) selectively inhibits AR activity in both androgen-dependent and castration-resistant AR-expressing prostate cancer cells. Int J Biochem Cell Biol. 2013 Apr; 45(4):763-72.
    View in: PubMed
    Score: 0.010
  14. Regulation of progesterone receptor activity by cyclin dependent kinases 1 and 2 occurs in part by phosphorylation of the SRC-1 carboxyl-terminus. Int J Biochem Cell Biol. 2011 Aug; 43(8):1157-67.
    View in: PubMed
    Score: 0.009
  15. 1a,25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest. Prostate. 2011 Jan 01; 71(1):98-110.
    View in: PubMed
    Score: 0.009
  16. 1{alpha},25-Dihydroxyvitamin D3 inhibits growth of VCaP prostate cancer cells despite inducing the growth-promoting TMPRSS2:ERG gene fusion. Endocrinology. 2010 Apr; 151(4):1409-17.
    View in: PubMed
    Score: 0.009
  17. Steroid receptor phosphorylation: Assigning function to site-specific phosphorylation. Biofactors. 2009 Nov-Dec; 35(6):528-36.
    View in: PubMed
    Score: 0.008
  18. Coactivator selective regulation of androgen receptor activity. Steroids. 2009 Aug; 74(8):669-74.
    View in: PubMed
    Score: 0.008
  19. 1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells. Endocrinology. 2009 May; 150(5):2046-54.
    View in: PubMed
    Score: 0.008
  20. Target gene-specific regulation of androgen receptor activity by p42/p44 mitogen-activated protein kinase. Mol Endocrinol. 2008 Nov; 22(11):2420-32.
    View in: PubMed
    Score: 0.008
  21. Androgen receptor coactivators and prostate cancer. Adv Exp Med Biol. 2008; 617:245-55.
    View in: PubMed
    Score: 0.007
  22. Interactions between vitamin D and androgen receptor signaling in prostate cancer cells. Nutr Rev. 2007 Aug; 65(8 Pt 2):S116-7.
    View in: PubMed
    Score: 0.007
  23. Steroid receptor phosphorylation: a key modulator of multiple receptor functions. Mol Endocrinol. 2007 Oct; 21(10):2311-9.
    View in: PubMed
    Score: 0.007
  24. Cyclins, cyclin dependent kinases, and regulation of steroid receptor action. Mol Cell Endocrinol. 2007 Feb; 265-266:157-61.
    View in: PubMed
    Score: 0.007
  25. Cyclin dependent kinase 2 and the regulation of human progesterone receptor activity. Steroids. 2007 Feb; 72(2):202-9.
    View in: PubMed
    Score: 0.007
  26. Androgens modulate expression of transcription intermediary factor 2, an androgen receptor coactivator whose expression level correlates with early biochemical recurrence in prostate cancer. Cancer Res. 2006 Nov 01; 66(21):10594-602.
    View in: PubMed
    Score: 0.007
  27. Androgen receptor action in hormone-dependent and recurrent prostate cancer. J Cell Biochem. 2006 Oct 01; 99(2):362-72.
    View in: PubMed
    Score: 0.007
  28. Identification of CAND1 as a DNA-dependent protein kinase-regulated coactivator of androgen receptor and the ARv7 splice variant. PLoS One. 2026; 21(5):e0349130.
    View in: PubMed
    Score: 0.007
  29. Dual roles for the phosphatase PPM1D in regulating progesterone receptor function. J Biol Chem. 2006 Mar 17; 281(11):7089-101.
    View in: PubMed
    Score: 0.006
  30. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Prostate. 2005 Sep 01; 64(4):362-72.
    View in: PubMed
    Score: 0.006
  31. Role of SRC-1 in the promotion of prostate cancer cell growth and tumor progression. Cancer Res. 2005 Sep 01; 65(17):7959-67.
    View in: PubMed
    Score: 0.006
  32. Vitamin D receptor agonists induce prostatic acid phosphatase to reduce cell growth and HER-2 signaling in LNCaP-derived human prostate cancer cells. J Steroid Biochem Mol Biol. 2005 Oct; 97(1-2):37-46.
    View in: PubMed
    Score: 0.006
  33. Role of insulin-like growth factor binding proteins in 1alpha,25-dihydroxyvitamin D(3)-induced growth inhibition of human prostate cancer cells. Prostate. 2005 Jun 15; 64(1):9-19.
    View in: PubMed
    Score: 0.006
  34. Human progesterone receptor displays cell cycle-dependent changes in transcriptional activity. Mol Cell Biol. 2005 Apr; 25(8):2885-98.
    View in: PubMed
    Score: 0.006
  35. Cyclin-dependent kinase activity is required for progesterone receptor function: novel role for cyclin A/Cdk2 as a progesterone receptor coactivator. Mol Cell Biol. 2005 Jan; 25(1):264-77.
    View in: PubMed
    Score: 0.006
  36. The functional consequences of cross-talk between the vitamin D receptor and ERK signaling pathways are cell-specific. J Biol Chem. 2004 Nov 05; 279(45):47298-310.
    View in: PubMed
    Score: 0.006
  37. 1alpha,25-dihydroxyvitamin D3 induced growth inhibition of PC-3 prostate cancer cells requires an active transforming growth factor beta signaling pathway. Prostate. 2004 May 15; 59(3):282-91.
    View in: PubMed
    Score: 0.006
  38. Vitamin D and prostate cancer. Exp Biol Med (Maywood). 2004 Apr; 229(4):277-84.
    View in: PubMed
    Score: 0.006
  39. Stable expression of full length human androgen receptor in PC-3 prostate cancer cells enhances sensitivity to retinoic acid but not to 1alpha,25-dihydroxyvitamin D3. Prostate. 2003 Sep 01; 56(4):293-304.
    View in: PubMed
    Score: 0.005
  40. Repressors of androgen and progesterone receptor action. J Biol Chem. 2003 Aug 15; 278(33):31136-48.
    View in: PubMed
    Score: 0.005
  41. The requirement for p42/p44 MAPK activity in progesterone receptor-mediated gene regulation is target gene-specific. Steroids. 2013 Jun; 78(6):542-7.
    View in: PubMed
    Score: 0.005
  42. p53 Is required for 1,25-dihydroxyvitamin D3-induced G0 arrest but is not required for G1 accumulation or apoptosis of LNCaP prostate cancer cells. Endocrinology. 2003 Jan; 144(1):50-60.
    View in: PubMed
    Score: 0.005
  43. A novel androgen receptor mutant, A748T, exhibits hormone concentration-dependent defects in nuclear accumulation and activity despite normal hormone-binding affinity. Mol Endocrinol. 2002 Dec; 16(12):2692-705.
    View in: PubMed
    Score: 0.005
  44. Vector-averaged gravity-induced changes in cell signaling and vitamin D receptor activity in MG-63 cells are reversed by a 1,25-(OH)2D3 analog, EB1089. Bone. 2002 Sep; 31(3):381-8.
    View in: PubMed
    Score: 0.005
  45. Uridine Diphosphate Glucuronosyl Transferase 2B28 (UGT2B28) Promotes Tumor Progression and Is Elevated in African American Prostate Cancer Patients. Cells. 2022 07 29; 11(15).
    View in: PubMed
    Score: 0.005
  46. Vitamin D and prostate cancer. J Androl. 2002 Jan-Feb; 23(1):9-17.
    View in: PubMed
    Score: 0.005
  47. Identification of a phosphorylation site in the hinge region of the human progesterone receptor and additional amino-terminal phosphorylation sites. J Biol Chem. 2001 Mar 16; 276(11):8475-83.
    View in: PubMed
    Score: 0.005
  48. A calcitriol analogue, EB1089, inhibits the growth of LNCaP tumors in nude mice. Cancer Res. 2000 Feb 15; 60(4):779-82.
    View in: PubMed
    Score: 0.004
  49. Calcitriol-induced apoptosis in LNCaP cells is blocked by overexpression of Bcl-2. Endocrinology. 2000 Jan; 141(1):10-7.
    View in: PubMed
    Score: 0.004
  50. A C619Y mutation in the human androgen receptor causes inactivation and mislocalization of the receptor with concomitant sequestration of SRC-1 (steroid receptor coactivator 1) Mol Endocrinol. 1999 Dec; 13(12):2065-75.
    View in: PubMed
    Score: 0.004
  51. Vitamin D and prostate cancer. Proc Soc Exp Biol Med. 1999 Jun; 221(2):89-98.
    View in: PubMed
    Score: 0.004
  52. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 2019 02; 38(7):1121-1135.
    View in: PubMed
    Score: 0.004
  53. Ligand-independent activation of steroid hormone receptors. J Mol Med (Berl). 1998 Jun; 76(7):469-79.
    View in: PubMed
    Score: 0.004
  54. Targeting the Hsp40/Hsp70 Chaperone Axis as a Novel Strategy to Treat Castration-Resistant Prostate Cancer. Cancer Res. 2018 07 15; 78(14):4022-4035.
    View in: PubMed
    Score: 0.004
  55. Role of Androgen Receptor Variants in Prostate Cancer: Report from the 2017 Mission Androgen Receptor Variants Meeting. Eur Urol. 2018 05; 73(5):715-723.
    View in: PubMed
    Score: 0.004
  56. Differential expression of uterine progesterone receptor forms A and B during the menstrual cycle. J Steroid Biochem Mol Biol. 1997 Nov-Dec; 63(4-6):195-202.
    View in: PubMed
    Score: 0.004
  57. Phosphorylation of human progesterone receptor by cyclin-dependent kinase 2 on three sites that are authentic basal phosphorylation sites in vivo. Mol Endocrinol. 1997 Jun; 11(6):823-32.
    View in: PubMed
    Score: 0.004
  58. Differential phosphorylation of chicken progesterone receptor in hormone-dependent and ligand-independent activation. J Biol Chem. 1997 Apr 18; 272(16):10457-63.
    View in: PubMed
    Score: 0.004
  59. 1,25-dihydroxyvitamin D3 and 9-cis-retinoic acid act synergistically to inhibit the growth of LNCaP prostate cells and cause accumulation of cells in G1. Endocrinology. 1997 Apr; 138(4):1491-7.
    View in: PubMed
    Score: 0.004
  60. Steroid hormone receptors and their regulation by phosphorylation. Biochem J. 1996 Nov 01; 319 ( Pt 3):657-67.
    View in: PubMed
    Score: 0.003
  61. Activation of the human androgen receptor through a protein kinase A signaling pathway. J Biol Chem. 1996 Aug 16; 271(33):19900-7.
    View in: PubMed
    Score: 0.003
  62. Phosphorylation of Ser211 in the chicken progesterone receptor modulates its transcriptional activity. J Biol Chem. 1996 May 31; 271(22):12801-6.
    View in: PubMed
    Score: 0.003
  63. Inhibition of the hexosamine biosynthetic pathway promotes castration-resistant prostate cancer. Nat Commun. 2016 05 19; 7:11612.
    View in: PubMed
    Score: 0.003
  64. Nuclear Receptor Corepressor 1 Expression and Output Declines with Prostate Cancer Progression. Clin Cancer Res. 2016 08 01; 22(15):3937-49.
    View in: PubMed
    Score: 0.003
  65. Differential Regulation of Progesterone Receptor-Mediated Transcription by CDK2 and DNA-PK. Mol Endocrinol. 2016 Feb; 30(2):158-72.
    View in: PubMed
    Score: 0.003
  66. Identification of a group of Ser-Pro motif hormone-inducible phosphorylation sites in the human progesterone receptor. Mol Endocrinol. 1995 Aug; 9(8):1029-40.
    View in: PubMed
    Score: 0.003
  67. Phosphorylation and progesterone receptor function. J Steroid Biochem Mol Biol. 1995 Jun; 53(1-6):509-14.
    View in: PubMed
    Score: 0.003
  68. Phosphorylation and steroid hormone action. Vitam Horm. 1995; 51:289-313.
    View in: PubMed
    Score: 0.003
  69. Identification of phosphorylation sites unique to the B form of human progesterone receptor. In vitro phosphorylation by casein kinase II. J Biol Chem. 1994 Dec 09; 269(49):31034-40.
    View in: PubMed
    Score: 0.003
  70. GATA2 facilitates steroid receptor coactivator recruitment to the androgen receptor complex. Proc Natl Acad Sci U S A. 2014 Dec 23; 111(51):18261-6.
    View in: PubMed
    Score: 0.003
  71. Phosphorylation of Ser530 facilitates hormone-dependent transcriptional activation of the chicken progesterone receptor. Mol Endocrinol. 1994 Nov; 8(11):1465-73.
    View in: PubMed
    Score: 0.003
  72. AR collaborates with ERa in aromatase inhibitor-resistant breast cancer. Breast Cancer Res Treat. 2014 Oct; 147(3):473-85.
    View in: PubMed
    Score: 0.003
  73. Multiple signaling pathways activate the chicken progesterone receptor. Mol Endocrinol. 1994 May; 8(5):577-84.
    View in: PubMed
    Score: 0.003
  74. Metabolomic profiling identifies biochemical pathways associated with castration-resistant prostate cancer. J Proteome Res. 2014 Feb 07; 13(2):1088-100.
    View in: PubMed
    Score: 0.003
  75. Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression. Int J Oncol. 2013 Jan; 42(1):35-43.
    View in: PubMed
    Score: 0.003
  76. Ligands induce conformational changes in the carboxyl-terminus of progesterone receptors which are detected by a site-directed antipeptide monoclonal antibody. Mol Endocrinol. 1992 Oct; 6(10):1585-97.
    View in: PubMed
    Score: 0.003
  77. A standards-based, peer-reviewed teaching award to enhance a medical school's teaching environment and inform the promotions process. Acad Med. 2012 Jul; 87(7):870-6.
    View in: PubMed
    Score: 0.003
  78. Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer. Cancer Res. 2011 Jan 15; 71(2):572-82.
    View in: PubMed
    Score: 0.002
  79. Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400. Mol Endocrinol. 2010 Feb; 24(2):335-45.
    View in: PubMed
    Score: 0.002
  80. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Mol Cancer Ther. 2009 Jul; 8(7):1787-98.
    View in: PubMed
    Score: 0.002
  81. Parathyroid hormone-related protein regulates cell survival pathways via integrin alpha6beta4-mediated activation of phosphatidylinositol 3-kinase/Akt signaling. Mol Cancer Res. 2009 Jul; 7(7):1119-31.
    View in: PubMed
    Score: 0.002
  82. Androgen receptor overexpression induces tamoxifen resistance in human breast cancer cells. Breast Cancer Res Treat. 2010 May; 121(1):1-11.
    View in: PubMed
    Score: 0.002
  83. PTHrP contributes to the anti-proliferative and integrin alpha6beta4-regulating effects of 1,25-dihydroxyvitamin D(3). Steroids. 2007 Dec; 72(14):930-8.
    View in: PubMed
    Score: 0.002
  84. International Union of Pharmacology. LXV. The pharmacology and classification of the nuclear receptor superfamily: glucocorticoid, mineralocorticoid, progesterone, and androgen receptors. Pharmacol Rev. 2006 Dec; 58(4):782-97.
    View in: PubMed
    Score: 0.002
  85. Quantifying effects of ligands on androgen receptor nuclear translocation, intranuclear dynamics, and solubility. J Cell Biochem. 2006 Jul 01; 98(4):770-88.
    View in: PubMed
    Score: 0.002
  86. Akt phosphorylates and suppresses the transactivation of retinoic acid receptor alpha. Biochem J. 2006 May 01; 395(3):653-62.
    View in: PubMed
    Score: 0.002
  87. Prostate cancer cell type-specific involvement of the VDR and RXR in regulation of the human PTHrP gene via a negative VDRE. Steroids. 2006 Feb; 71(2):102-15.
    View in: PubMed
    Score: 0.002
  88. c-Jun N-terminal kinase contributes to aberrant retinoid signaling in lung cancer cells by phosphorylating and inducing proteasomal degradation of retinoic acid receptor alpha. Mol Cell Biol. 2005 Feb; 25(3):1054-69.
    View in: PubMed
    Score: 0.002
  89. A germline variation in the progesterone receptor gene increases transcriptional activity and may modify ovarian cancer risk. J Clin Endocrinol Metab. 2004 Dec; 89(12):6340-7.
    View in: PubMed
    Score: 0.001
  90. Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cells. Clin Cancer Res. 2004 Dec 01; 10(23):8018-27.
    View in: PubMed
    Score: 0.001
  91. Regulation of Bcl-2 expression by dihydrotestosterone in hormone sensitive LNCaP-FGC prostate cancer cells. J Urol. 2003 Apr; 169(4):1553-7.
    View in: PubMed
    Score: 0.001
  92. Molecular analysis of the androgen receptor in ten prostate cancer specimens obtained before and after androgen ablation. J Androl. 2003 Mar-Apr; 24(2):215-25.
    View in: PubMed
    Score: 0.001
  93. Mechanistic differences in the activation of estrogen receptor-alpha (ER alpha)- and ER beta-dependent gene expression by cAMP signaling pathway(s). J Biol Chem. 2003 Apr 11; 278(15):12834-45.
    View in: PubMed
    Score: 0.001
  94. Identification of a transferable two-amino-acid motif (GT) present in the C-terminal tail of the human lutropin receptor that redirects internalized G protein-coupled receptors from a degradation to a recycling pathway. Mol Endocrinol. 2003 Mar; 17(3):411-22.
    View in: PubMed
    Score: 0.001
  95. Novel nonsecosteroidal vitamin D receptor modulator inhibits the growth of LNCaP xenograft tumors in athymic mice without increased serum calcium. Prostate. 2001 Nov 01; 49(3):224-33.
    View in: PubMed
    Score: 0.001
  96. Use of the probasin promoter ARR2PB to express Bax in androgen receptor-positive prostate cancer cells. J Natl Cancer Inst. 2001 Sep 05; 93(17):1314-24.
    View in: PubMed
    Score: 0.001
  97. Androgen receptors and their biology. Vitam Horm. 2001; 62:199-230.
    View in: PubMed
    Score: 0.001
  98. Androgen receptor mutations in prostate cancer. Cancer Res. 2000 Feb 15; 60(4):944-9.
    View in: PubMed
    Score: 0.001
  99. Differential hormone-dependent phosphorylation of progesterone receptor A and B forms revealed by a phosphoserine site-specific monoclonal antibody. Mol Endocrinol. 2000 Jan; 14(1):52-65.
    View in: PubMed
    Score: 0.001
  100. Species, interindividual, and tissue specificity in endocrine signaling. Environ Health Perspect. 1999 Aug; 107 Suppl 4:619-24.
    View in: PubMed
    Score: 0.001
  101. 7alpha-Iodo and 7alpha-fluoro steroids as androgen receptor-mediated imaging agents. J Med Chem. 1999 Jun 03; 42(11):2021-34.
    View in: PubMed
    Score: 0.001
  102. Polyglutamine-expanded androgen receptors form aggregates that sequester heat shock proteins, proteasome components and SRC-1, and are suppressed by the HDJ-2 chaperone. Hum Mol Genet. 1999 May; 8(5):731-41.
    View in: PubMed
    Score: 0.001
  103. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: integration of hormone signaling in reproduction and stress. Mol Cell. 1999 Apr; 3(4):521-6.
    View in: PubMed
    Score: 0.001
  104. The nuclear corepressors NCoR and SMRT are key regulators of both ligand- and 8-bromo-cyclic AMP-dependent transcriptional activity of the human progesterone receptor. Mol Cell Biol. 1998 Mar; 18(3):1369-78.
    View in: PubMed
    Score: 0.001
  105. Stoichiometry and site-specific phosphorylation of human progesterone receptor in native target cells and in the baculovirus expression system. J Biol Chem. 1996 Aug 09; 271(32):19546-55.
    View in: PubMed
    Score: 0.001
  106. Two types of anti-progestins have distinct effects on site-specific phosphorylation of human progesterone receptor. J Biol Chem. 1996 Jan 12; 271(2):1209-17.
    View in: PubMed
    Score: 0.001
  107. Progesterone receptor and the mechanism of action of progesterone antagonists. J Steroid Biochem Mol Biol. 1995 Jun; 53(1-6):449-58.
    View in: PubMed
    Score: 0.001
  108. An alternative ligand-independent pathway for activation of steroid receptors. Recent Prog Horm Res. 1995; 50:333-47.
    View in: PubMed
    Score: 0.001
  109. 1,25-dihydroxyvitamin D3 modulates phosphorylation of serine 205 in the human vitamin D receptor: site-directed mutagenesis of this residue promotes alternative phosphorylation. Biochemistry. 1994 Apr 12; 33(14):4300-11.
    View in: PubMed
    Score: 0.001
  110. The progesterone antagonist RU486 acquires agonist activity upon stimulation of cAMP signaling pathways. Proc Natl Acad Sci U S A. 1993 May 15; 90(10):4441-5.
    View in: PubMed
    Score: 0.001
  111. Modulators of cellular protein phosphorylation alter the trans-activation function of human progesterone receptor and the biological activity of progesterone antagonists. Breast Cancer Res Treat. 1993; 27(1-2):41-56.
    View in: PubMed
    Score: 0.001
  112. Hormone and antihormone induce distinct conformational changes which are central to steroid receptor activation. J Biol Chem. 1992 Sep 25; 267(27):19513-20.
    View in: PubMed
    Score: 0.001
  113. Effects of hormone and cellular modulators of protein phosphorylation on transcriptional activity, DNA binding, and phosphorylation of human progesterone receptors. Mol Endocrinol. 1992 Apr; 6(4):607-20.
    View in: PubMed
    Score: 0.001
  114. High level expression of biologically active estrogen receptor in Saccharomyces cerevisiae. J Steroid Biochem Mol Biol. 1991 Sep; 39(3):291-7.
    View in: PubMed
    Score: 0.001
  115. Regulation of in vitro transcription by progesterone receptor. Characterization and kinetic studies. J Biol Chem. 1990 Mar 25; 265(9):5129-34.
    View in: PubMed
    Score: 0.001
  116. The progesterone receptor stimulates cell-free transcription by enhancing the formation of a stable preinitiation complex. Cell. 1990 Jan 26; 60(2):247-57.
    View in: PubMed
    Score: 0.001
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.